Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)
  7. Epidemiology and Biostatistics (153)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Surgery (123)
  10. Survivorship Research (120)
Search Within
Formats
  1. Journal Article (751)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (11)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (566)
  2. Solid Tumor Oncology Division (461)
  3. GSK Faculty (295)
  4. Sloan Kettering Institute Postdocs (194)
  5. Hematologic Malignancies, Division of (160)
  6. Population Sciences Research Program (158)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (26)

More People

Years
  1. 2025 (40)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (412)
  2. Breast Cancer Research (67)
  3. BMC Cancer (65)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1092)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b/2 randomized study of Avb-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment
    Meeting Abstract

    Beckermann, K.; Vogelzang, N.; Shifeng, M.; Ornstein, M.; Shah, N.; Hammers, H.; Campbell, M.; Gao, X.; McDermott, D.; Anderson, R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Keynote-495/keyimpact: Interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (Nsclc)
    Meeting Abstract

    Gutierrez, M.; Lam, W. S.; Hellmann, M.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase 1 trial of cue-101, a novel Hpv16 E7-Phla-Il2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic Hpv16+ head and neck cancer
    Meeting Abstract

    Chung, C.; Colevas, A. D.; Gibson, M.; Adkins, D.; Sukari, A.; Wirth, L.; Burtness, B.; Bauman, J.; Rodriguez, C.; Worden, F.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): Long-term efficacy and safety update from a phase 1b/2 study
    Meeting Abstract

    Makker, V.; Aghajanian, C.; Cohn, A.; Romeo, M.; Bratos, R.; Brose, M.; Messing, M.; Dutta, L.; Dutcus, C.; Huang, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors
    Meeting Abstract

    Kuryk, L.; Moller, A. S.; Kumar, S.; Shoushtari, A.; Ares, L. P.; Jaderberg, M.; Wiklund, E. D.; Levitsky, V.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Biomarker correlates of response in patients with advanced myxoid/round cell liposarcoma (MRCLS) treated with NY-ESO-1 TCR T Cells (letetresgene autoleucel)
    Meeting Abstract

    Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Eleftheriadou, I.; Huff, A.; Nathenson, M.; Druta, M.; Van Tine, B.; Somaiah, N.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma
    Meeting Abstract

    McKean, M.; Luke, J.; Lakhani, N.; Bashir, B.; Aggen, D.; Tan, A.; Kacena, K.; Wang, L.; Timothy, M.; Santillana, S.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase I/II trial of intracerebroventricular 177lu DTPA omburtamab radioimmunotherapy for leptomeningeal metastasis from solid tumors
    Meeting Abstract

    Pentsova, E.; Dùˆring, M.; Lind, C. L.; Nielsen, J. R.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-Cell production and immunotherapy response in metastatic breast cancer
    Meeting Abstract

    Page, D.; Collins, K.; Chun, B.; Sun, Z.; Koguchi, Y.; Redmond, W.; Martel, M.; Wu, Y.; Moxon, N.; Mellinger, S.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
    Meeting Abstract

    Zhang, J.; Caushi, J.; Oliveira, G.; Zhang, B.; Ji, Z.; Naidoo, J.; Marrone, K.; Taube, J.; Hellmann, M.; Brahmer, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save